



Express Mail Mailing Label No. EV289510060US

PATENT

Attorney Docket No. LEX-002C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies *et al.* CONF. NO.: 6802
SERIAL NO.: 10/005,212 GROUP NO.: 1646
FILING DATE: December 4, 2001 EXAMINER: Mertz, P.M.
TITLE: Heterodimeric Fusion Proteins Useful for Targeted Immune Therapy and General Immune Stimulation

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

This paper is responsive to the Office action mailed from the U.S. Patent and Trademark Office on January 14, 2004, for the above-referenced patent application. Applicants enclose a Terminal Disclaimer and accompanying fee.

Amendments to the Claims are shown beginning on page 2 of this paper.

Remarks begin on page 4 of this paper.


04/29/2004 ISSUE
01 FEB 2001
0000003 200531 10005112
65.00 DA

respectfully request that the rejection of the pending claims under 35 U.S.C. § 103(a) be reconsidered and withdrawn.

Conclusion

Claims 1-3 and 23-27 are pending and believed to be in condition for allowance.
Examiner Mertz is invited to telephone the undersigned attorney to discuss any remaining issues.

Respectfully submitted,



Michael H. Brodowski
for Brian A. Fairchild
Attorney for Applicant(s)
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: April 14, 2004
Reg. No. 41,640

Tel. No.: (617) 248-7012
Fax No.: (617) 248-7100

3048903